Sadeghi Zohre, Fasihi-Ramandi Mahdi, Davoudi Zahra, Bouzari Saeid
Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
J Pharm Sci. 2023 Apr;112(4):991-999. doi: 10.1016/j.xphs.2022.12.025. Epub 2023 Jan 6.
One promising approach to increase protection against infectious diseases is to use adjuvants that can selectively stimulate the immune responses. In this study, multi-epitope antigens associated with LPS loaded chitosan (LLC) as toll-like receptor agonist or mannosylated chitosan nanoparticle (MCN) as vaccine delivery system were evaluated for their ability to stimulate immune responses to Brucella infection in mice model. Our results indicated that the addition of MCN to our vaccine formulations significantly elicited IFN-γ and IL-2 cytokines and antibody titers, in comparison with the non-adjuvanted vaccine candidates. The present results indicated that multi-epitopes and their administration with LLC or MCN induced Th1 immune response. In addition, vaccine candidates containing MCN provided high percentage of protection against B. melitensis and B. abortus infection. Our results provided support to previous reports indicating that MCNs are attractive adjuvants and addition of this adjuvant to multi-epitopes antigens play an important role in the development of vaccine against Brucella.
一种增强对传染病防护的有前景的方法是使用能够选择性刺激免疫反应的佐剂。在本研究中，评估了与作为 toll 样受体激动剂的 LPS 负载壳聚糖（LLC）或作为疫苗递送系统的甘露糖基化壳聚糖纳米颗粒（MCN）相关的多表位抗原刺激小鼠模型中针对布鲁氏菌感染的免疫反应的能力。我们的结果表明，与无佐剂的候选疫苗相比，在我们的疫苗制剂中添加 MCN 显著引发了 IFN-γ 和 IL-2 细胞因子以及抗体滴度。目前的结果表明，多表位及其与 LLC 或 MCN 的联合给药诱导了 Th1 免疫反应。此外，含有 MCN 的候选疫苗对羊种布鲁氏菌和牛种布鲁氏菌感染提供了高比例的保护。我们的结果为先前的报告提供了支持，表明 MCN 是有吸引力的佐剂，并且将这种佐剂添加到多表位抗原中在抗布鲁氏菌疫苗的开发中起着重要作用。
